Skip to main content
Uncategorized

The Biomed Division of Leitat and GP-Pharm have demonstrated the efficacy of Docetaxel in the fight against ovarian cancer

By 27 de May de 2010No Comments
< Back to news
 27.05.2010

The Biomed Division of Leitat and GP-Pharm have demonstrated the efficacy of Docetaxel in the fight against ovarian cancer

The Biomed Division of Leitat –based at the Barcelona Science Park (PCB)- has collaborated with GP Pharm, a pharmaceutical company of the Lipotect group- in the conductance of comparative efficacy studies on the new formulations of Docetaxel, a drug manufactured by GP Pharm, and the current standard of treatment -Taxotere®- for ovarian cancer. The outcome of this joint research study- supported by the Centre for Technological and Industrial (CDTI) of the Ministry of Industry- demonstrates that these new formulations of Docetaxel produce an antitumoral effect similar to that of Taxotere. This finding will enable researchers to continue their research with a view to developing new drugs based on these new formulations.

The Biomed Division of Leitat and GP Pharm presented the conclusions of this research at the international conference “Towards Personalized Cancer Medicine”, which was held in the New York Academy of Sciences, in Talència and in the Social Programme of “la Caixa”. The organising committee of the congress was composed, among others, by IRB Barcelona, through its adjunct director, Joan Massagué; the Vall Hebron Institute of Oncology (VHIO), through Josep Baselga; and the Institute of Predictive and Personalised Centre Medicine (IMPCC), through Manuel Perucho. Other participants of the congress included Nobel Prize winner in Medicine (1989) J. Michael Bishop, who gave the opening lecture entitled “Genome and cancer therapy”.

The Leitat Technological Centre has been focusing its activity on the research and development of new therapies against cancer for the last two years when they created their Biomed Division, located at the PCB. Over these two years, this division has developed “ad hoc personalised research” for third parties and has taken part in collaboration projects with GP Pharm and other pharmaceutical and biotechnological companies, being the most important among these several CDTI, Zenit and Nucli projects. Hand in hand with the above, the Biomed Division has been developing its own therapeutic pipeline against cancer diseases and on the diagnosis and monitoring of treatments.